The Pathophysiology of Ovarian Hyperstimulation Syndrome (OHSS)

Despite the fact that it was first described over thirty years ago, the factors responsible for (OHSS) have continued to elude investigators. During this time, several theories have been popularized but none have become widely accepted. Recently, it has been suggested that angiotensin II (Ang II) derived from the ovary plays an important role in the development of OHSS (1). This paper will briefly review previous theories and present the results of experiments performed at the University of Southern California School of Medicine that add weight to the notion that ODPAC is involved in OHSS. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58: 249–261. Golan A, Ronel R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation: An update review. Obstet Gynecol Surv. 1989; 44: 430–440. McClure N, Leya J, Radwanska E, Rawlins R, Haning RV. Luteal phase support and severe ovarian hyperstimulation syndrome. Hum Reprod. 1992; 7: 758–764. Ferrareti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine treatment for severe hyperstimulation syndrome. Hum Reprod. 1992; 7: 180–183. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril. 1969; 20: 443–447. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril. 1978; 20: 443–448. Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, David A, Serr DM, Salomy M. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet. 1965; ii: 1213–1215. Haning RV, Strawn EY, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol. 1985; 66: 220–225. Engel T, Jewelicz R, Dyrenfurth I, Speroff L, Vande Wiele RL. Ovarian hyperstimulation syndrome. Amer J Obstet Gynecol. 1972; 112: 1052–1060. Davis JS. Hormonal control of plasma and erythrocyte volume of rat uterus. Amer J Physiol. 1960; 199: 841–846. Miles RA, Lobo RA, Paulson RJ, Sauer MV. The use of testolactone to prevent ovarian hyperstimulation syndrome (OHSS) after gonadotropin therapy. Abstract. Presented at the th meeting of the Society for Gynecologic Investigation. 1992. Hurwitz A, Krausz M, Eldar-Geva T, Yagel S, Schenker JG, Palti Z, Laufer N. Production of 6-keto-PGF1α in hyperstimulated cycles: In vivo and in vitro studies. Int J Fertil. 1991; 36: 252–256. Armstrong DT, Grinwich DL. Blockade of spontaneous and LH-induced ovulation in rats by indomethacin, an inhibitor of prostaglandin biosynthesis. Prostaglandins. 1972; 1: 21–28. Pride SM, Ho Yuen B, Moon YS, Leung PCS. Relationship og gonadotropin releasing hormone, danazol, and prostaglandin blockade to ovarian enlargement and ascites formation of the ovarian hyperstimulation syndrome in the rabbit. Amer J Obstet Gynecol. 1986; 154: 1155–1160. Zaidise I, Friedman M, Lindenbaum ES, Askenazi R, Peretz BA, Paldi E. Serotonin and the ovarian hyperstimulation syndrome. Europ J Obstet Gynecol Reprod Biol. 1983; 15: 55–60. Erlik Y, Naot Y, Friedman M, Ben-David E, Paldi E. Histamine levels in ovarian hyperstimulation syndrome. Obstet Gynecol. 1979; 53: 580–582. Szego CM, Gitin ES. Ovarian histamine depletion during acute hyperemic response to luteinizing hormone. Nature. 1964; 201:682. Knox GE. Antihistamine blockade of the ovarian hyperstimulation syndrome. Amer J Obstet Gynecol. 1974; 118: 992–994. Loukides JA, Loy RA, Edwards R, Honig J, Visintin I, Polan ML. Human follicular fluids contain tissue macrophages. J Clin Endoc Metab. 1990; 71: 1363–1367. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril. 1993; 60: 826–833. Culler MD, Tarlatzis BC, Lightman A, Fernandez LA, DeCherney AH, Negro-Vilar A, Naftolin F. Angiotensin II-like immunoreactivity in human ovarian follicular fluid. J Clin Endoc Metab. 1986; 62: 613–615. Derkx FHM, Alberda AT, Zeilmaker GH, Schalekamp MADH. High concentrations of immunoreactive renin, prorenin, and enzymatically-active renin in human ovarian follicular fluid. Br J Obstet Gynecol. 1987; 94: 4–9. Itskovitz J, Rubattu S, Levron J, Sealey JE. Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. J Clin Endoc Metab. 1992; 75: 906–910. Bisset GS, Lewis GP. Spectrum of pharmacological activity in some biologically active peptides. Br J Pharmacol. 1962; 19: 168–182. Robertson AL, Khairallah PA. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res. 1972; 31: 923–931. Morel NML, Petruzzo PP, Hechtman HB, Shepro D. Inflammatory agonists that increase microvascular permeability in vivo stimulate cultured pulmonary microvessel endothelial cell contraction. Inflammation. 1990; 14: 571–582. Franken AAM, Derkx FHM, Schalekamp MADH, Manint’Veld AJ, Hop WCJ, van Rens, EH, de Jong PTVM. Association of high plasma prorenin with diabetic nephropathy. J Hypert. 1988; 6s4:s461–s463. Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graef Arch Clin Exper Opthalm. 1990; 228: 505–509. Ikeda T, Nakayama D, Gomi T, Sakurai J, Yamazaki T, Yuhara M. Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron. 1989; 52: 72–75. Ruilope LM, Miranda B, Oliet A, Millet VG, Rodicio JL, Romer JC, Raij L. Control of hypertension with the angiotesnin converting enzyme inhibitor captopril reduces glomerular proteinuria. J Hypert. 1988; 6s4:s467–s469. Stornello M, Valvo EV, Puglia N, Scapellato L. Angiotensin converting enzyme inhibition with a low dose of enalapril in normotensive diabetics with persistent proteinuria. J Hypert. 1988; 6s4:s464–s466. Navot D, Margoliath EJ, Laufer N, Birkinfeld A, Relou A, Rosier A, Schenker JG. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril. 1987; 48: 57–61. Ong ACM, Eisen V, Rennie DP, Homburg R, Lachelin GCL, Jacobs HS, Slater JDH. The pathogenesis of the ovarian hyperstimulation syndrome (OHS): a possible role for ovarian renin. Clin Endoc. 1991; 34: 43–49. Morris RS, Wong IL, Hatch IE, Paulson RJ, Lobo RA. Prorenin is elevated in PCO and may reflect hyperandrogensim. Abstract presented at the XXth meeting of the Society for Gynecologic Investigation. Chicago, IL. March 1994. Submitted to the J of the Soc Gyn Invest. Morris RS, Wong IL, Gentschein E, Sauer MV, Lobo RA, and Paulson RJ. Angiotensin converting enzyme inhibition for the prevention of ovarian hyperstimulation syndrome: A randomized prospective, placebo controlled double blind trial. Abstract presented at the th meeting of the Pacific Coast Fertility Society, Indian Wells, CA April 19–23, 1994. Submitted to Hum Reprod. Morris RS, Wong IL, Paulson RJ. Angiotensin converting enzyme inhibition in the gonadotropin stimulated rabbit: effect on estradiol production. Submitted to Fertil Steril. Morris RS, Lindheim SR, Paulson RJ, McConnel RA, Sauer MV. Angiotensin converting enzyme inhibition dramatically reverses lutealphase steroid production in oocyte donors. Abstract presented at the 38th Annual meeting of the American Fertility Society. Montreal, Canada, March 1994. Submitted to Fertil Steril. Author information Authors and Affiliations Editor information Editors and Affiliations Rights and permissions Copyright information © 1995 Springer Science+Business Media New York About this chapter Cite this chapter Morris, R.S. et al. (1995). The Pathophysiology of Ovarian Hyperstimulation Syndrome (OHSS). In: Mukhopadhyay, A.K., Raizada, M.K. (eds) Tissue Renin-Angiotensin Systems. Advances in Experimental Medicine and Biology, vol 377. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0952-7_28 Download citation DOI: https://doi.org/10.1007/978-1-4899-0952-7_28 Publisher Name: Springer, Boston, MA Print ISBN: 978-1-4899-0954-1 Online ISBN: 978-1-4899-0952-7 eBook Packages: Springer Book Archive

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.